0000950123-11-074841.txt : 20110809 0000950123-11-074841.hdr.sgml : 20110809 20110809120723 ACCESSION NUMBER: 0000950123-11-074841 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110809 DATE AS OF CHANGE: 20110809 EFFECTIVENESS DATE: 20110809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 111019641 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 w83980e13fvhr.txt FORM 13F-HR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: June 30, 2011 Check here if Amendment [ ]; Amendment Number: __________ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Pascal Schmucki Title: SIGNING AUTHORITY Phone: 41 (44) 267 67 00 Signature, Place, and Date of Signing: /s/ Pascal Schmucki ----------------------------------------- Schaffhausen, Switzerland, August 08, 2011 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 3 Form 13F Information Table Entry Total: 19 Form 13F Information Table Value Total: $1,066,275 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name --- -------------------- ---- 1 28-11193 Biotech Focus N.V. 2 28-11191 Biotech Invest N.V. 3 28-11189 Biotech Target N.V. 2 BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 ---------------------- -------- --------- -------- ------------------ ---------- -------- --------------------- VOTING AUTHORITY TITLE VALUE SHS OR SH/ PUT/ INVESTMENT OTHER --------------------- NAME OF ISSUER OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ---- Achillion Pharmaceuticals Inc COM 00448Q201 9,877 1,327,540 SH DEFINED 3 1,327,540 NONE NONE Affymetrix Inc COM 00826T108 8,132 1,025,518 SH DEFINED 1 1,025,518 NONE NONE Alexion Pharmaceuticals Inc COM 015351109 24,173 514,000 SH DEFINED 2 514,000 NONE NONE Amgen Inc COM 031162100 29,175 500,000 SH DEFINED 1 500,000 NONE NONE Amylin Pharmaceuticals Inc COM 032346108 36,246 2,713,055 SH DEFINED 2 2,713,055 NONE NONE Biomarin Pharmaceutical Inc COM 09061G101 26,545 975,545 SH DEFINED 2 975,545 NONE NONE Celgene Corp COM 151020104 244,986 4,061,446 SH DEFINED 2 4,061,446 NONE NONE Dendreon Corp COM 24823Q107 46,322 1,174,500 SH DEFINED 2 1,174,500 NONE NONE Gilead Sciences Inc COM 375558103 141,647 3,420,609 SH DEFINED 1 3,420,609 NONE NONE Halozyme Therapeutics Inc COM 40637H109 34,550 5,000,000 SH DEFINED 3 5,000,000 NONE NONE Human Genome Sciences Inc COM 444903108 21,376 871,056 SH DEFINED 2 871,056 NONE NONE Idenix Pharmaceuticals Inc COM 45166R204 15,507 3,101,308 SH DEFINED 3 3,101,308 NONE NONE Immunogen Inc COM 45253H101 47,843 3,924,778 SH DEFINED 3 3,924,778 NONE NONE Incyte Corp COM 45337C102 86,461 4,565,000 SH DEFINED 3 4,565,000 NONE NONE Isis Pharmaceuticals COM 464330109 45,220 4,936,642 SH DEFINED 3 4,936,642 NONE NONE Micromet Inc COM 59509C105 38,351 6,681,397 SH DEFINED 3 6,681,397 NONE NONE Optimer Pharmaceuticals Inc COM 68401H104 24,351 2,048,003 SH DEFINED 3 2,048,003 NONE NONE Theravance Inc. COM 88338T104 14,731 663,244 SH DEFINED 3 663,244 NONE NONE Vertex Pharmaceuticals Inc COM 92532F100 170,782 3,284,903 SH DEFINED 3 3,284,903 NONE NONE
3